Costs of bleeding on long-term antiplatelet treatment without routine co-prescription of proton-pump inhibitors.

ABSTRACT:

Background

Long-term antiplatelet treatment is associated with major bleeding.

Aims

To determine the costs associated with major bleeding in patients treated with aspirin-based antiplatelet treatment for secondary prevention of vascular events without routine prescription of proton-pump inhibitors and to estimate the likely long-term savings from routine co-prescription.

Methods

In a prospective population-based cohort study of TIA, ischemic stroke, and MI treated with antiplatelet drugs, we evaluated hospital care costs associated with bleed management during 10-year follow-up. Bleeding-associated costs were averaged across all patients. For upper GI-bleeds, mean costs were compared with the cost of routine co-prescription of proton-pump inhibitor.

Results

Amo

SUBMITTER: Luengo-Fernandez R 

PROVIDER: S-EPMC7611493 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature